Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Natriuretic peptide [NP; B‐type NP (BNP), N‐terminal proBNP (NT‐proBNP), and
midregional proANP (MR‐proANP)] concentrations are quantitative plasma biomarkers for …

Since the inception of the Canadian Cardiovascular Society heart failure (HF) guidelines in
2006, much has changed in the care for patients with HF. Over the past decade, the HF …

Diagnosing heart failure is often difficult due to the non‐specific nature of symptoms, which
can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been …

Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of
brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of …

The purpose of this focused update is to update the “2013 ACCF/AHA Guideline for the
Management of Heart Failure” 9 (2013 HF guideline) in areas in which new evidence has …

Acute heart failure is a major cause of urgent hospitalizations. These are followed by marked
increases in death and rehospitalization rates, which then decline exponentially though they …

ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Background We assessed the prognostic significance of absolute and percentage change in
N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients hospitalised for …

Purpose Acute heart failure (AHF) causes high burden of mortality, morbidity, and repeated
hospitalizations worldwide. This guidance paper describes the tailored treatment …